BERKELEY, Calif.--(BUSINESS WIRE)--July 12, 2006--XOMA Ltd. (Nasdaq:XOMA - News) today announced that LUCENTIS(TM), owned by Genentech, Inc. (NYSE:DNA - News) and recently approved by the FDA for the treatment of neovascular (wet) age-related macular degeneration, is the first marketed therapeutic product by a licensee of XOMA's Bacterial Cell Expression (BCE) technology. XOMA will receive a royalty on worldwide sales of LUCENTIS(TM). Another drug, CIMZIA(TM) (certolizumab pegol, CDP870), owned by UCB (Euronext-Brussels:UCB), has been submitted to the FDA and European regulators for approval in Crohn's disease and is currently in Phase 3 clinical trials for rheumatoid arthritis.
